| | Patient demographics | All patients (n = 648) |
| | Age, median, year (IQR) | 75 (68–80) | | Overall survival, median, month (IQR) | 48 (24–106) | | Time to CRPC, median, month (IQR) | 16.5 (8–36) | | M stage, n (%) | | 1A | 72 (11.11%) | | 1B | 492 (75.93%) | | 1C | 84 (12.96%) | | Gleason grade group, n (%) | | 1 | 8 (1.5%) | | 2 | 18 (3.38%) | | 3 | 60 (11.26%) | | 4 | 111 (20.83%) | | 5 | 336 (63.04%) | | Missing | 115 | | Initial PSA level, ng/ml, median (IQR) | 243.9 (74.9–790.8) | | Hb, g/dL, median (IQR) | 12.1 (10.3–13.5) | | Ca, g/dL, median (IQR) | 8.7 (8.3–9.1) | | ALP, U/L, median (IQR) | 118 (75–227) | | CRPC, n (%) | | Yes | 375 (57.9%) | | No | 273 (42.1%) | | PSA kinetics after ADT | | TTN, month, median (IQR) | 8.7 (4.8–16.65) | | Nadir PSA level, ng/ml, median (IQR) | 0.86 (0.07–5.99) | | PSARR, %/month, median (IQR) | 10.32 (5.62–18.17) | | TFNTC, month, median (IQR) | 4.5 (2.7–15.1) | | PSADT, month, median (IQR) | 2.6 (1.5–5.3) |
|
|
CRPC: castration-resistant prostate cancer, TTN: time to PSA nadir, PSARR: PSA reduction rate, TFNTC: time from PSA nadir to CRPC, and PSADT: PSA doubling time.
|
